Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study

Current Therapeutic Research - Clinical and Experimental

Volumn 69, Issue 1, 2008, Pages 1-15

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Mugellini, Amedeo ^a   Preti, Paola ^a   Destro, Maurizio ^a   Rinaldi, Andrea ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

hydrochlorothiazide; hypertension; olmesartan; telmisartan

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN; OLPRESS; TELMISARTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 41249095681     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2008.02.003     Document Type: Article

References (39)

1. Chobanian A., Bakris G., Black H., et al., for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA 289 (2003) 2560-2572
2. 2003 European Society of Hypertension-European Society of Cardidogy guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
3. Turnbull F., and for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular events: Results of prospectively- designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
4. Staessen J., Wang J., and Thijs L. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens 21 (2003) 1055-1076
5. Hansson L., Zanchetti A., Carruthers S., et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
6. UK Prospective Diabetes Study Group. Tight blood pressure contrd and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
7. Yusuf S., Sleight P., Pogue J., et al., for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342:1376 and N Engl J Med. 2000;342:748]. N Engl J Med 342 (2000) 145-153
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA 288 (2002) 2981-2997
9. Moser M., and Black H. The rde of combination therapy in the treatment of hypertension. Amy Hypertens 11 (1998) 73S-78S
10. Sica D. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 62 (2002) 443-462
11. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 1 (2003) 43-50
12. Palatini P. Combination therapy in the management of hypertension: Focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens 7 (2005) 96-101
13. Kjeldsen S., Os I., HOieggen A., et al. Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Amy Cardiovasc Drugs 5 (2005) 17-22
14. McInnes G., O'Kane K., Istad H., et al. Comparison of the ATl-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens 14 (2000) 263-269
15. Palatini P., Mugellini A., Spagnudo V., et al., for the Investigators Group. Comparison of the effects on 24-h ambulatory blood pressure ofvalsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press Monit 9 (2004) 91-97
16. Rump L., Ambrosioni E., Burnier M., et al. Initial combination therapy with olmesartan/ hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 20 (2006) 299-301
17. Hansson L., Hedner T., and Dahlöf B. Prospective, randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1 (1992) 113-119
18. Groppelli A., Omboni S., Ravogli A., et al. Validation of the SpaceLabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens Suppl 9 (1991) S334-S335
19. Parati G., Bosi S., Castellano M., et al., Guidelines for 24-h non-invasive ambulatory blood pressure monitoring. Report from a working group of the Italian Society of Hypertension. High Blood Press 4 (1995) 168-174
20. Omboni S., Parati G., Zanchetti A., and Mancia G. Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: Methodological aspects. J Hypertens 13 (1995) 1105-1112
21. Rose M., and McMahon F. Some problems with antihypertensive drug studies in the context of the new guidelines. Amy Hypertens 3 (1990) 151-155
22. Rizzoni D., Castellano M., Muiesan M., et al. Beyond trough:peak ratio: A new index of the smoothness of the antihypertensive effect of a drug. High Blood Press 6 (1997) 110-115
23. Parati G., Omboni S., Rizzoni D., et al. The Smoothness Index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 16 (1998) 1685-1691
24. Freytag F., Schelling A., Meinicke T., Deichsel G., and for the Telmisartan Hypertension Experience in a Randomized European Study Versus Atenold Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: A randomized, multicenter study. Clin Thef 23 (2001) 108-123
25. McGill J., and Reilly P. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 23 (2001) 833-850
26. Schmieder R. Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. Expert Opin Pharmacother 5 (2004) 2303-2310
27. Maillard M., and Burnier M. Telmisartan/hydrochlorothiazide: A new fixed dose combination. Expert Rev Cardiovasc Ther 3 (2005) 375-386
28. Chrysant S., and Chrysant G. Antihypertensive efficacy of dmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother 5 (2004) 657-667
29. Sellin L., Stegbauer J., Laeis P., and Rump L. Adding hydrochlorothiazide to dmesartan dose dependently improves 24-h blood pressure and response rates in mild-to moderate hypertension. J Hypertens 23 (2005) 2083-2092
30. Fogari R., Zoppi A., Mugellini A., et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately contrdled by monotherapy. Adv Ther 23 (2006) 680-695
31. McClellan K., and Markham A. Telmisartan. Drugs 56 (1998) 1039-1044
32. Nussberger J., and Koike H. Antagonizing the angiotensin II subtype I receptor: A focus on dmesartan medoxomil. Clin Thef 26 (2004) A12-A20
33. Turnbull F. Effectsofdifferent blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
34. Turnbull F., Neal B., Algert C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Ned 165 (2005) 1410-1419
35. Mancia G. Role of outcome trials in providing information on antihypertensive treatment: Importance and limitations. Am J Hypertens 19 (2006) 1-7
36. Liu L., Zhang Y., Liu G., et al. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 23 (2005) 2157-2172
37. Lithell H., Hansson L., Skoog I., et al., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
38. Meredith P. Role of trough to peak efficacy in the evaluation of antihypertensive therapy. J Hypertens Suppl 16 (1998) S59-S64
39. Palatini P., Penzo M., Racioppa A., et al. Clinical relevance of nighttime blood pressure and day- time blood pressure variability. Arch Intern Ned 152 (1992) 1855-1860